Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT01672164

Discovery and Validation of Proteogenomic Biomarker Panels in Liver Transplant Recipients

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

View on ClinicalTrials.gov

Summary

The main focus of this study is to develop blood and/or urine tests that will help to detect early signs of rejection in people who have had a liver transplant. Researchers will examine blood, urine, and tissue samples and try to identify markers for certain conditions such as rejection, response to therapy, and scarring of the liver. Additionally, researchers would like to identify biomarkers that can detect damage to the native kidneys before blood levels of creatinine rises. By studying gene expression, researchers hope to be able to diagnose these conditions earlier and improve liver survival.

Official title: Discovery and Validation of Proteogenomic Biomarker Panels in a Prospective Serial Blood and Urine Monitoring Study of Liver Transplant Recipients - Transplant Proteogenomics

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

202

Start Date

2012-08

Completion Date

2015-12

Last Updated

2026-09-25

Healthy Volunteers

No

Locations (6)

Mayo Clinic

Phoenix, Arizona, United States

Northwestern University, Feinberg School of Medicine

Chicago, Illinois, United States

Mount Sinai School of Medicine

New York, New York, United States

Cleveland Clinic Foundation

Cleveland, Ohio, United States

Medical University of South Carolina

Charleston, South Carolina, United States

Baylor University Medical Center

Dallas, Texas, United States